Pegvisomant

( DrugBank: Pegvisomant / KEGG DRUG: Pegvisomant )

2 diseases

ID	Disease name (Link within this page)	Number of trials
78	Hypopituitarism	2

ID	Disease name (Link within this page)	Number of trials
265	Lipodystrophy	1

78. Hypopituitarism

Clinical trials : 492 / Drugs : 341 - (DrugBank : 47) / Drug target genes : 45 - Drug target pathways : 100

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01804413 (ClinicalTrials.gov)	March 2011	18/2/2013	Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency	Effects of Pegvisomant-Priming With the Glucagon Stimulation Test in Assessing GH and Cortisol Reser ...	Adults Growth Hormone Deficiency.	Drug: Pegvisomant;Drug: Regular insulin	Oregon Health and Science University	Aarhus University Hospital	Recruiting	21 Years	55 Years	Both	10	N/A	United States
2	NCT00468624 (ClinicalTrials.gov)	December 2004	2/5/2007	Effect of Pegvisomant on GH/IGF-I Relationship in GHD	A Study of the Relationship Between Serum Growth Hormone (GH) and Insulin-Like Growth Factor One (IG ...	Severe Adult Growth Hormone Deficiency	Drug: pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks;Procedure: GH samp ...	Christie Hospital NHS Foundation Trust	NULL	Terminated	18 Years	70 Years	Both		N/A	United Kingdom

Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05470504 (ClinicalTrials.gov)	January 23, 2023	16/7/2022	Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance	Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance	Insulin Receptor Mutation;Partial Lipodystrophy	Drug: Pegvisomant	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Recruiting	18 Years	65 Years	All	25	Phase 2	United States